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ABSTRACT
Selective estrogen receptor modulators (SERMs) are a class of molecules that activate estrogen receptors (ER), impacting differently on different 
tissues. Upon binding to ER, the ligand-receptor complex may present various conformations due to the presence of two different kinds of ERs. Few 
of these ligands show estrogenic effects, whereas others will inhibit the action of estrogens. Researchers are working in the direction to generate 
the SERMs that have a desirable estrogen-like effects on the various sites i.e., bones, improving lipid profile, reduce hot flushes, but do not act like 
estrogens in unwanted ways i.e., causing breast cancer, uterine endometrial proliferation. Given the comprehensive nature of this article, it is not our 
intention to revisit many of the issues relating to SERMs, which have already been covered in detail. Rather this article focuses on the aspect that 
ligand-mediated structural perturbations in and around the ligand binding pocket, contributed by the side chain effects lead to receptor antagonism. 
Adjusting the balance of these effects may provide a novel strategy for designing of improved SERMs. In the light of this, the article will provide an 
overview of the SERMs and their structural diversity.
Keywords: Ligand and estrogen receptor, Side chain of selective estrogen receptor modulators, Selective estrogen receptor modulators, Mechanism 
of action.
INTRODUCTION
Over the years, anti-estrogens have been used as a potential treatment 
of hormone dependent neoplasm and also the object of increasing 
intensive study. Estrogens are the components crucial to female 
physiology. They have been sadly neglected because they have rather 
unjustly earned a bad name, continuously linking estrogen use with 
breast cancer and entrometrial cancer. Despite all these scares, they 
are able to prevent postmenopausal osteoporosis and to successfully 
palliate the symptoms of perimenopause i.e., hot flushes, fatigue, 
insomnia and headache, incontinence, changes in blood lipid profile 
(i.e., increased low density lipoprotein [LDL], cholesterol)and various 
abnormalities consequent upon vasomotor instability [1-4]. Estrogens, 
a classic structural array of compounds that are involved in growth 
development and homoeostasis of a number of tissues [5]. They 
function via binding to two ligand inducible nuclear transcription factor, 
Estrogen receptor (ER) α and β. Ligands Initiate a series of molecular 
events, upon binding to ligand binding domain (LBD) of ER, culminating 
in the activation or repression of target gene, subsequently producing 
some response [5]. There are various representative of this estrogen 
group like 17 β-estradiol, estrone, estrioles, phytoestrogens such as 
coumestrol and genistein, synthetic estrogens like diethylstilbestrol 
(DES), and various other xenobiotics [6-11]. As an alternative to 
estrogen replacement therapy, selective ER modulators (SERMs)are 
now also the members of this estrogen family [12]. SERMs work in a 
manner, acting as estrogen agonist in extracellular tissues (liver, bone, 
brain)while having no effect or antagonizing the estrogenic response in 
reproductive tissues (uterus, breast) [13]. This tissue selective spectrum 
of SERMs was explored out via studies with various deletion and point 
mutated receptors. Studies reveal two independent transcription 
activation domains activation function 1 (AF1)and AF2 within the 
receptor that allow the expression of cell and promoter specific agonist 
activity [14]. SERMs act in a very selective way causing induction of 
unique receptor conformation in which the antagonist activity in some 
tissues is a result of functional AF1 domains [15,16]. Crystal structure 
studies conducted on LBD of ER in complex with the endogenous 
estrogens 17 β-estradiol, synthetic non-steroidal estrogens, DES and 
selective antagonist raloxifene (RAL) [6,7] show that stilbene portion of 
tamoxifene (first SERM to be clinically used)was required for F1 activity 
leading to agonist respond in bone and ethanol amine side chain was 
responsible for blocking the AF2 activity leading to antagonism in the 
uterus [17]. It is now apparent that antagonist activity of anti-estrogens 
is due to the presence of a long carbon chain at position 7 α or 11 β 
or any equal location in the steroids and steroids like skeleton. Side 
chain makes hydrophobic interactions with amino acids of the ER’s 
LBD [18,19]. The growing realization of the significant role of the side 
chain in the modulating activity of SERMs in various physiological 
processes resulted in extensive research in this area. Several excellent 
publications over the recent years, describe the crucial role played by 
the side chain in maintaining the tissue selective agonist and antagonist 
activity. The contributions by Brzozowski et al. [20], Pike [21], Walker 
et al. [22], together with the most recent work are the excellent starting 
point for anyone intending to enter this field.
STRUCTURAL BASIS OF AGONISM AND ANTAGONISM
All ER ligands bind exclusively to the C-terminal LBD and this LBD 
recognizes a variety of compounds diverse in their shape, size and 
chemical properties. Most non-steroidal selective estrogens so far 
available, share a common pharmacophore which consists of two aryl 
groups separated by two atoms, often in stilbene framework. Beside 
all these, the SERMs typically bear a third aryl group containing a 
4-amino ethoxy substitution. Transcriptional activity manifested by 
ER, is mediated by at least two activation functions AF-1 at N-terminus 
and AF-2 in LBD [7](Fig. 1). Mitogen-activated protein kinase pathway 
is involved in regulating AF-1 and AF-2 binding is responsive to ligand 
binding [23,24]. Recent X-ray co-crystallographic studies of structures 
of LBD complexed with E2, DES, RAL and 4-OH tamoxifen (or OH-T, a high 
affinity metabolite of tamoxifen)show that although all these ligands 
bind at the same site within the core of LBD but these ligand induce 
differential conformation of helix-12 of ER. helix-12 in E2-LBD complex 
packs against helices 3, 5/6, 11 in a conformation that is common to the 
agonist bound NR-LBD structure. While in RAL-LBD complex, helix 12 
lies in a hydrophobic groove composed of residues from helices 3 and 5. 
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This specialized orientation of helix-12, partially buries residues in the 
groove that are necessary for AF-2 functions suggesting that RAL and 
other antagonist block AF-2 functions by disrupting the topography of 
the AF2 surface [22]. Studies showed that OH-T is also bound within the 
same pocket that retains the DES, E2 and RAL. The orientation of OH-T 
within the binding pocket appears to be established by two structural 
features of the ligand, the phenolic A ring and bulky side chain [25] 
(Fig. 2a and b). The A ring of OH-T is bounded in nearly the same 
way as the ring A of DES and E2 near the helices 3 and 6. Its phenolic 
hydroxyl hydrogen bonding to structurally conserved water molecule 
and to the side chain of Glu-353 and Arg-394 [26]. The side chain of 
OH-T exits the binding pocket between helices 3 and 11 (like in RAL) 
[25] while its C ring makes van der waals contact with the side chain of 
Met-343, Leu-346, Thr-347, Ala-350, Trp-383 and salt bridge between 
the dimethyl amino group of the side chain and β-carboxylate of Asp 
351. The positioning of the A ring and the side chain in the context 
of rigid triphenylethylene framework of the OH-T requires that the 
ethylene group of OH-T in an orientation nearly orthogonal to that 
of ethylene group of DES [26]. As a result, the B ring is driven more 
deeply into the binding pocket than A ring of DES. As a consequence 
of this side chain induced conformation, many inter-residue Vander 
waal contacts present in the DES and E2 complex, are now lacking in 
OH-T complex [25,26]. The binding of OH-T to ER induces a helix 12 
conformation that inhibits the binding of coactivator. That leads helix 12 
being prevented from being positioned over the ligand binding pocket 
by the OH-T side chain [26]. The side chain of RAL and other SERMs, 
like that of OH-T, sterically hinders the agonist bound conformation of 
helix-12, thereby interference of coactivator recruitment can interferes 
with the cellular transcription and thus allow SERM to behave as an 
antagonist on the target gene with a given cell type [27]. It makes clear 
that the tissue selectivity of various SERMs may is due to its ability to 
block particular coactivator recruitment site on the surface of the ER-
LBD. Selective antagonism of this kind exhibited by various prototypes 
is a complicated phenomenon that arises through interplay of a 
number of factors including differential ligand effect (mainly caused 
by side chain)on the trans activation functionalities of the ER, the 
type of coactivator recruited and the cell and promoter context. From 
these mechanistic studies, it is clear that certain well-characterized 
modulators such as heat shock proteins and a number of others 
maintain the inactive state of the receptor. Binding of the ligand leads 
to the dissociation of these chaperones and convert the receptor into 
a DNA binding form [11] and activated ligand-receptor complex then 
interacts with specific DNA sequences. However, coactivators mediate 
this ligand (agonist)dependent activation of transcription. Several 
proteins including steroid receptor coactivator-1 (SRC-1)/N-CoA1, 
GR1P1/TIF2/N-CoA2 and CBP/P300 act as a coactivator by associating 
in the ligand-dependent manner with ER and several NRs. Coactivators 
SRC-1 and GR1P1, being the member of P160 family of coactivators, 
recognize the agonist bound NRLBDs through a short signature motif L 
is leucine and X is an aminoacid known as NR box. And the antagonist 
mediates its response by blocking coactivator binding [28]. Activated 
complex interacts with specific DNA sequence and is, usually, located a 
couple of hundred base pair upstream the regulated gene. It modulate 
the genomic expression by influencing the synthesis of m-RNA and 
thereby respective protein thus producing cellular response [28]. 
These mechanistic studies discussed above give valuable insight into 
the binding of the ligand to the receptor thus can provide a sound basis 
for structure based design of improved SERMs.
VARIOUS GENERATIONS AND CLASSES OF SERMS
Historically a no. of nonsteroidal compounds, capable of interacting 
ERs, have been found as contraceptive and for the treatment of breast 
cancer, uterine dysfunction and other complications concerning female 
reproductive system. A frequently used strategy designing most 
of the SERMs, was the attachment of a basic side chain chemically, 
to a molecule or resembling molecules that interact with the ER 
such as 17 β-estradiol or DES. The generation of tamoxifen from 
DES can be taken as prine example. Tamoxifen being the first SERM 
characterized as an anti-estrogen in the treatment of breast cancer. 
Subsequent to its development for the same, it was observed that 
tamoxifen exhibited estrogen agonist effect on the skeleton and the 
liver. However, unfortunate finding with this was its stimulatory 
effect on uterine endometrium, thereby increasing the risk of uterine 
cancer. The second generation of SERMs includes the compounds 
RAL [27], droloxifen [29], idoxifen [29] and levormetoxifen [29]. 
RAL was developed and marketed mainly for osteoporotic disorders. 
RAL efficiently reduces LDL cholesterol. However, it has been shown 
to exacerbate vasomotor instability as well. It has no proliferative 
effects on uterus and breast thereby preventing from any risk of 
neoplastic breast and endrometrium [27]. Third generation of SERMs 
lasoxifene, TSE-424 have improved profile over RAL. Though these 
candidate drugs lack any uterine or breast stimulation, but also lack 
relief from vasomotor instability. For years, a considerable effort has 
gone into synthesizing an ideal SERMs having efficacy as an equivalent 
replacement for hormone replacement therapy.
CONCLUSION
Knowledge of the role of the side chain of SERMs in activity modulation 
is becoming increasingly well defined. Now in present scenario the 
Fig. 1: Estrogen receptor and its domains [30]
Fig. 2: (a and b) Receptor binding with E2 and TAM [30]
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development of SERMs for various bone diseases, breast and uterine 
disorders can be more apparently understood in context of two 
different ERα and ERβ, their interaction with ligand with variable 
affinities, orientation of side chain of SERMs in receptor core and 
cellular, biochemical and structural aspects of ER and ligand. The 
tissue-selective conformation of ER-ligand complex regulates the 
phosphorylation and recruitment of a variety of coactivators and 
corepressors, which in turn decides upon the transcriptional response. 
Understanding various critical aspects ER-ligand complex and more 
specific tissue selective role of side chain of SERMs will definitely 
provide sound basis for developing novel SERMs with target based 
optimal activity and minimal side effects and that will serve society as 
therapeutic agent.
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